Larry Lasky is a Partner at The Column Group, where he invests in early-stage biotech companies with a focus on severe diseases. Previously, Dr. Lasky was a partner at USVP, where he was a founding or co-founding investor of Cleave Biosciences, eFFECTOR and Calithera Biosciences. As a general partner and co-founder of Latterell Venture Partners from 2002 to 2007, Dr. Lasky was the founding investor of Proteolix (acquired by Onyx Pharmaceuticals) and OncoMed Pharmaceuticals and was instrumental in the founding of Cellective Therapeutics (acquired by Medimmune), Tetralogic and BioVerdant. Prior, Dr. Lasky served as a scientist, senior scientist and later Genentech Fellow at Genentech over the course of 20 years. Dr. Lasky holds B.A. and Ph.D. degrees in molecular biology from the University of California, Los Angeles and completed his post-doctoral studies at The California Institute of Technology.